Abstract:Abstract Voltage-gated sodium channels are crucial for pain perception. This is illustrated by several human genetic conditions that lead to either chronic pain or, vice versa, to congenital painlessness. The type of mutation, its impact on neuron excitability as well as the affected sodium channel subtype delineates a complex picture of the disorders. Genetic variants in sodium channels may affect the complex biophysical gating and also their trafficking, association with other proteins and more complex regulations of the channel protein and function, thus allowing us to explore the subtle but impactful effects of their dysregulation for human nociception. A detailed understanding of these pain disorders provides a unique chance to understand the detailed intricacies of nociception and pathological conditions such as neuropathic pain. With increasing awareness of the importance of sodium channel variants in neuropathic pain, more patients are genetically screened, sometimes identifying variants of unclear significance (VUS). Bioinformatic tools help to assess their potential disease causing impact, but functional studies using patch-clamp experiments in cell lines are needed to allow for reliable conclusions. Often cell lines are not sufficient to show a physiologically relevant phenotype and more complex, time intensive models, such as induced pluripotent stem cells (iPS-cells) are employed. A challenge remains to identify the role of each sodium channel VUS in the context of the detailed cellular genetic and functional context. To lay the grounds for such a detailed interpretation, we need a correlation of cellular function and genetic transcription on a single cell basis, as it is possible with the Patch-Seq technique. The more detailed our knowledge becomes on functional and genetic sensory neurons subtypes and their role in the generation of neuropathic pain, the more targeted the personal or population-based treatment can be.

The physiological function of different voltage-gated sodium channels in pain

Sodium Channel Inhibitors (Nav1.7, 1.8, And 1.9) For Neuropathic Pain Management

Analgesic potential of voltage gated sodium channel modulators for the management of pain

Human pain channelopathies

Progress in the Study of Voltage-Gated Sodium Channel Nav1.7 in Pain

Genetics meets function in sodium channel-related pain disorders

Insights into the voltage-gated sodium channel, NaV1.8, and its role in visceral pain perception

Similar excitability through different sodium channels and implications for the analgesic efficacy of selective drugs

Interplay of Nav1.8 and Nav1.7 channels drives neuronal hyperexcitability in neuropathic pain

Sodium channels expressed in nociceptors contribute distinctly to action potential subthreshold phase, upstroke and shoulder

A Gain-of-function Voltage-Gated Sodium Channel 1.8 Mutation Drives Intense Hyperexcitability of A- and C-fiber Neurons.

Mini-review - Sodium Channels and Beyond in Peripheral Nerve Disease: Modulation by Cytokines and Their Effector Protein Kinases.

Defining the Functional Role of NaV1.7 in Human Nociception

Recent advances in small molecule Nav 1.7 inhibitors for cancer pain management

Persistent (Nav1.9) sodium currents in human dorsal root ganglion neurons

Ion Channel Genes in Painful Neuropathies

Selective Voltage-Gated Sodium Channel Peptide Toxins from Animal Venom: Pharmacological Probes and Analgesic Drug Development

Computational modeling to study the impact of changes in Nav1.8 sodium channel on neuropathic pain

Unique electrophysiological property of a novel Nav1.7, Nav1.8, and Nav1.9 sodium channel blocker, ANP-230

Differential Inhibition of Nav1.7 and Neuropathic Pain by Hybridoma-Produced and Recombinant Monoclonal Antibodies that Target Nav1.7

Differential Inhibition of Nav1.7 and Neuropathic Pain by Hybridoma-Produced and Recombinant Monoclonal Antibodies That Target Nav1.7 : Differential Activities of Nav1.7-targeting Monoclonal Antibodies.